To: RYAN Dermot (CAB-HOGAN)
Cc: [redacted] (AGRI); [redacted] (AGRI); BASCOU Pierre (AGRI); [redacted] (AGRI)
Subject: Minutes of meeting with the Glyphosate Task Force - 13 Jan 2016

Short minutes of the meeting with the Glyphosate Task Force

Present: [redacted] *(Hume Brophy),* [redacted] *(ADAMA),* [redacted] *(Monsanto), Mr D. Ryan (CAB-HOGAN),* [redacted] *(AGRI D.2)*
Date: 13 January 2016, 11.15 am –12.00 noon.

The meeting was organized following a request from the Glyphosate Task Force.

It is the visitors' interest to assure the extension of authorization of glyphosate.

The visitors reported about the meeting they have had with the SANTE cabinet one hour earlier:
No further extension of authoristion, but a decision on renewal of authorization should be found until summer 2016. Up to now, there would be very little feedback about Member States' views. They reported that the Standing Committee should see a legislative proposal very soon, to be able to discuss (maybe in March) and to vote (maybe in May or June) on the proposal. The visitors judged the Commission as reluctant to propose something that would be criticized or rejected by the European Parliament. They wondered how the EP should be 'taken on board'. Even if non-binding, an objection by the EP should be avoided.

The visitors saw rejection of glyphosate from parliamentarians of different parties. They said that it has been very difficult to explain the subject to MEPs and that it would be interesting to explore ComAGRI-members views.

The difference between IARC and EFSA evaluations of glyphosate was briefly touched. GTF stated that IARC has looked at narrow data while EFSA has compiled a comprehensive risk assessment.

The visitors clearly stated that in the future authorization of glyphosate they do not want to see limitations linked to 'data gaps', need for review or further MS's assessments. They were strongly against a limitation of uses or the exclusion of so-called 'non-essential uses' as pre-harvest use of glyphosate (which is already restricted in several MS).

The acute reference dose (ARFD) was no issue of concern for GTF.

20/01/2016, [redacted]